This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an open-label, uncontrolled 'proof of concept study' to determine if gleevec, when given to HIV-1 infected individuals will decrease the amount of collagen in the TZ of lymph nodes. The primary endpoint is reduction of fibrosis. Secondary endpoints are increase in peripheral and TZ CD4+ T cell count.
Showing the most recent 10 out of 724 publications